|
|
News Breaks
|
November 8, 2009
|
| 13:43 EDT |  | HALO |
| theflyonthewall.com: | Halozyme Therapeutics announces positive results from insulin variability study | | Halozyme Therapeutics announced insulin variability study results that demonstrated reduced intrasubject absorption variability for the combination of lispro, a meal time analog insulin, plus PH20 compared to subcutaneous injection of lispro alone. When compared to lispro alone, the combination of lispro with PH20 reduced the variability for early and late insulin absorption, the time to maximum concentration, and the area under the curve at 15, 30, 60 and 120 minutes. The variability for maximum concentration was not affected. In addition, study results confirmed previously reported acceleration for both insulin absorption and action by coadministration of PH20. The company presented these study results this evening at the Diabetes Technology Society meeting in San Francisco. :theflyonthewall.com |
|
|
News For HALO From The Last 14 Days Check below for free stories on HALO the last two weeks.
There are 5 items on the Fly with pertinent information.
Sign up for a free trial to see the rest of the stories you've been missing. |
|
February 10, 2012
|
| 09:22 EDT |  | HALO |
| | 08:51 EDT |  | HALO |
|
|
February 9, 2012
|
| 16:17 EDT | | HALO |
| | 16:02 EDT | | HALO |
|
|
January 31, 2012
|
| 16:16 EDT | | HALO |
|
|
|
|
|
Subscribe for More Information